The Longevity Core

Three compounds, three different levers on cellular aging. GHK-Cu shifts gene expression toward a repair phenotype and drives collagen synthesis — the skin and tissue-density effects are downstream of that. Epithalon is the telomerase-activation candidate from the Khavinson peptide work: long on Russian clinical data, thinner on Western replication, and we say so plainly. NAD+ restores the substrate that sirtuins and mitochondrial metabolism burn through — levels decline with age, and repletion is the most boring, best-supported piece of the stack.

This is for people playing the long game: you're past quick fixes, your baseline habits are handled, and you want a structured pass at the cellular layer. Be honest about expectations — a 12-week commitment where the wins are quiet and compounding. Sleep architecture and energy tend to move first, skin density later. Nothing here is a stimulant arc, and anyone promising you'll feel Epithalon is selling something.

The protocol earns its price in structure: cycling schedules for each compound (they don't run concurrently the whole 12 weeks), the TMG pairing that protects methylation capacity from NAD+ flux — the detail most people skip, then wonder why they feel flat — plus before-and-after bloodwork, storage guidance, and exit criteria. Not a shortcut. A 12-week commitment with a defined end.